Rupesh Parikh, MD
Hematology & Oncology · Henderson, NVNPI 1245249689
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,964 of the $67,331 with a category attached, or 66.8%. 58 manufacturers reported payments, led by Bayer at 27.2% of the total. Reporting peaked in 2022 at $18,717 and has fallen 58.1% since, to $7,849 in 2025.
Across 658 payments — averaging $102.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$18K
- Beigene USA, Inc.$7K
- Daiichi Sankyo Inc.$6K
- Acceleron Pharma, Inc.$4K
- AstraZeneca$4K
- CTI Biopharma Corp.$3K
- plus $25K from 52 others
Across 25 payments — averaging $4971.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$58K
- Merck$37K
- Bristol Myers Squibb$24K
- Novartis$4K
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$319
What the payments were for
- Consulting fees$44,96467%
- Speaking & faculty fees$6,65610%
- Travel & lodging$2,5134%
- Food & beverage$11,43217%
- Education$1,7653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,331 in reported general payments places this provider in the 85th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 54 | $733,731 |
| JakafiRuxolitinib Phosphate | 36 | $648,717 |
| PomalystPomalidomide | 18 | $468,075 |
| RevlimidLenalidomide | 16 | $375,861 |
| CabometyxCabozantinib S-Malate | 15 | $374,672 |
| Lenalidomide | 22 | $316,002 |
| CalquenceAcalabrutinib Maleate | 34 | $315,952 |
| BrukinsaZanubrutinib | 27 | $279,096 |
| TagrissoOsimertinib Mesylate | 14 | $238,615 |
| VenclextaVenetoclax | 19 | $224,457 |
| ErleadaApalutamide | 14 | $194,240 |
| EliquisApixaban | 143 | $142,733 |
| Abiraterone Acetate | 37 | $127,609 |
| XareltoRivaroxaban | 74 | $83,065 |
| Erlotinib Hcl | 17 | $13,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $393 | $733,73154 claims |
| Incyte CorporationJakafi | $174 | $648,71736 claims |
| AstraZenecaCalquence, Tagrisso | $3,741 | $554,56748 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $927 | $468,07518 claims |
| Bristol Myers SquibbRevlimid | $306 | $375,86116 claims |
| Exelixis Inc.Cabometyx | $355 | $374,67215 claims |
| Beigene USA, Inc.Brukinsa | $7,059 | $279,09627 claims |
| Johnson & JohnsonErleada, Xarelto | $254 | $277,30488 claims |
| AbbVieVenclexta, Synthroid | $184 | $227,49356 claims |
| PfizerEliquis | $331 | $142,733143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Henderson
- Anthony NguyenHenderson$210K
- Russell GollardHenderson$105K
- Ramalingam RatnasabapathyHenderson$25K
- Stephani ChristensenHenderson$10K
- Resty TibayanHenderson$10K
- Nutan ParikhHenderson$10K
- Muhammad GhaniHenderson$9K
- Khoi DaoHenderson$8K
- Gilbert NyamuswaHenderson$4K
- Nicholas VogelzangLas Vegas$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.